Associate Scientist III, Mechanistic Cell Biology

Associate Scientist III, Mechanistic Cell Biology wanted by Insitro, Inc. in South San Francisco, CA. Designing, validating and performing biochemical and cell-based assays, as well as analyze/interpret data, to expand understanding of target engagement and downstream signaling pathways of multiple targets across a variety of therapeutic modalities; Building and optimizing transient and stable reporter cell lines (luciferase and fluorescence-based) to generate reliable and robust screening assays for drug candidates; Maintaining cultures of immortalized and primary cell lines and work with difficult cell models including iPSCs to perform biobanking, cell differentiation and cell-based assays involving genetic manipulation using siRNA and/or CRISPR, as well as handling and processing of tissue and plasma samples from in vivo studies; Working cross-functionally with scientists from diverse therapeutics areas and functions at Insitro to help answer mechanistic questions and to support assay development, experimental design, troubleshooting, sample analysis, data interpretation, and report generation.

 

Must have a Master's degree in Biotechnology, Biochemistry, Cell Biology or a related field plus two (2) years of experience in any occupation which includes the required experience/skills. Must also have two (2) years of experience developing, optimizing and performing end-point and image-based assays in 96- and 384-well plate formats (or other high-throughput formats) including ELISA assays and Luminex multiplex assays using cell and tissue samples; two (2) years of experience with transient and stable cell line reporter generation and using a wide range of molecular biology techniques including cloning, plasmid purification, gene editing, qPCR (Quantstudio), RNA isolation and protein quantification by western blot; two (2) years of experience with immunophenotyping, cell sorting and development of functional assays using advanced flow cytometry techniques (8+ color panels); two (2) years of experience utilizing aseptic technique for cell culture and handling immortalized cell lines, primary cells, iPSCs, as well as processing of rodent tissue and plasma samples; and two (2) years of experience with GraphPad Prism, Benchling and FlowJo (flow cytometry analysis software) software. In lieu of a Master's degree plus two (2) years of experience, we will accept a Bachelor's degree in Biotechnology, Biochemistry, Cell Biology or a related field plus five (5) years of progressive experience in any related occupation. Must also have three (3) years of experience developing, optimizing and performing end-point and image-based assays in 96- and 384-well plate formats (or other high-throughput formats) including ELISA assays and Luminex multiplex assays using cell and tissue samples; two (2) years of experience with transient and stable cell line reporter generation and using a wide range of molecular biology techniques including cloning, plasmid purification, gene editing, qPCR (Quantstudio), RNA isolation and protein quantification by western blot; three (3) years of experience with immunophenotyping, cell sorting and development of functional assays using advanced flow cytometry techniques (8+ color panels); two (2) years of experience utilizing aseptic technique for cell culture and handling immortalized cell lines, primary cells, iPSCs, as well as processing of rodent tissue and plasma samples; and two (2) years of experience with GraphPad Prism, Benchling and FlowJo (flow cytometry analysis software) software. $112,258-$125,000. Please send resume to: ta-resumes@insitro.com and refer to: Job Req. 2025-insitro-001P

 

Compensation & Benefits at insitro

Our target starting salary for successful US-based applicants for this role is $112,258-$125,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.

This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.

 

In addition, insitro also provides our employees:

• 401(k) plan with employer matching for contributions
• Excellent medical, dental, and vision coverage (insitro pays 100% of premiums for employees on our base plans), as well as mental health and well-being support
• Open, flexible vacation policy
• Paid parental leave
• Quarterly budget for books and online courses for self-development
• Support to occasionally attend professional conferences that are meaningful to your career growth and development
• New hire stipend for home office setup
• Monthly cell phone & internet stipend
• Access to free onsite baristas and cafe with daily lunch and breakfast
• Access to free onsite fitness center
• Commuter benefits

 

insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.

We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.

 

#LI-DNI

About insitro   insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.